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Abstract
Treatment with the anti-leukemic drug arsenic trioxide (As2O3, 1–4 μM) sensitizes U937 promonocytes and other human myeloid leukemia cell
lines (HL60, NB4) to apoptosis induction by TNFα. As2O3 plus TNFα increases TNF receptor type 1 (TNF-R1) expression, decreases c-FLIPL
expression, and causes caspase-8 and Bid activation, and apoptosis is reduced by anti-TNF-R1 neutralizing antibody and caspase-8 inhibitor. The
treatment also causes Bax translocation to mitochondria, cytochrome c and Omi/HtrA2 release from mitochondria, XIAP down-regulation, and
caspase-9 and caspase-3 activation. Bcl-2 over-expression inhibits cytochrome c release and apoptosis, and also prevents c-FLIPL down-regulation
and caspase-8 activation, but not TNF-R1 over-expression. As2O3 does not affect Akt phosphorylation/activation or intracellular GSH content, nor
prevents the TNFα-provoked stimulation of p65-NF-κB translocation to the nucleus and the increase in NF-κB binding activity. Treatments with
TNFα alone or with As2O3 plus TNFα cause TNF-R1-mediated p38-MAPK phosphorylation/activation. P38-MAPK-specific inhibitors attenuate
the As2O3 plus TNFα-provoked activation of caspase-8/Bid, Bax translocation, cytochrome c release, and apoptosis induction. In conclusion, the
sensitization by As2O3 to TNFα-induced apoptosis in promonocytic leukemia cells is an Akt/NF-κB-independent, p38-MAPK-regulated process,
which involves the interplay of both the receptor-mediated and mitochondrial executioner pathways.
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Arsenic trioxide (As2O3, Trisenox™) is a clinically effective
drug in the cure of acute promyelocytic leukemia (APL). At low
concentrations (≤4 μM in plasma) As2O3 causes APL cyto-
reduction by promoting cell differentiation and/or apoptosis.
This property was originally attributed to the capacity of the drug
to disrupt the promyelocytic leukemia-retinoic acid receptor α
(PML-RARα) fusion protein, characteristic of most APLs [1].
Nonetheless, As2O3 exhibits multiple effects which are also
important for apoptosis [1,2]. This offers the possibility of
extending the therapeutic use of the drug to malignancies other
than APLs, and actually promising pre-clinical assays have been
carried out using different hematological and solid tumour cell
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types to As2O3 would require generating strategies to increase
the apoptotic efficacy of the drug, and decrease the dosage to
clinically affordable concentrations.
As2O3 is a mitochondria-targeting drug, which binds the
adenosine nucleotide translocator [4] and interferes with
mitochondrial respiration [5]. As most chemotherapeutic
agents, As2O3 may induce apoptosis by activating the
“intrinsic” (mitochondrial) pathway. This pathway is char-
acterized by the release of cytochrome c and other mito-
chondrial proteins to the cytosol, assembly and activation of
the apoptosome and inhibition of IAPs (“inhibitor of apoptosis
proteins”), and sequential activation of caspase-9 and effector
caspases [6]. Hence, a manner of potentiating As2O3 toxicity
may be the combination with cytokines of the tumour necrosis
factor alpha (TNFα) family, which activate the “extrinsic”
(receptor-mediated) pathway. This pathway is initiated by
cytokine binding and activation of death receptors (TNF-Rs),
followed by DISC (“death-inducing signalling complex”)
formation and activation of initiator caspase-8 (or -10) and
effector caspases [6]. Among these cytokines, tumour necrosis
factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is
considered a promising anticancer agent because of its
capacity to preferentially induce apoptosis in tumour cells
with lower toxicity to normal cells [7]. The use of TNFα
itself has been questioned because of the low sensitivity of
many tumour cells and the inflammatory response induced by
high doses of this cytokine [8]. Nevertheless, it has been
argued that combined treatments allowing a reduction in
dosage may still render TNFα effective as an anticancer
agent [9,10].
Earlier reports indicated that As2O3 cooperate with TRAIL to
induce apoptosis in human leukemia cell lines [11,12]. As2O3
stimulated cytokine receptor expression and down-regulated c-
FLIP (“FLICE-inhibitory protein”) expression, and these effects
were in turn mediated by Akt dephosphorylation [12]. On the
ground of these observations, we wanted to investigate the
possible cooperation between As2O3 and TNFα to induce
apoptosis in leukemia cells. We selected the U937 promonocytic
cell line as an appropriate model, since it exhibits low intrinsic
sensitivity to both As2O3 [13] and TNFα [14]. The obtained
results indicate that As2O3 sensitizes U937 and other myeloid
leukemia cells to apoptosis induction by TNFα. Apoptosis
behaves as an Akt/NF-κB-independent, p38-MAPK-regulated
process, which involves TNF-R1 over-expression, c-FLIPL
down-regulation, and caspase-8 activation. Nonetheless, As2O3
plus TNFα also activates the mitochondrial pathway, which
regulates the activation of the receptor-mediated pathway.
2. Materials and methods
2.1. Reagents and antibodies
All components for cell culture were obtained from Invitrogen, Inc.
(Carlsbad, CA, USA). 4,6-diamino-2-phenylindole (DAPI) was obtained from
Serva (Heidelberg, Germany). The kinase inhibitors LY294002, PD98059,
U0126, SB203580, SB220025, and SP600125, the caspase substrates N-acetyl-
Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNA, specific for caspase-3) andN-acetyl-Leu-Glu-His-Asp-p-nitroanilide (Ac-LEHD-pNA, specific for cas-
pase-9), and the caspase inhibitors Z-Val-Ala-Asp(OMe)-CH2F (z-VAD-fmk,
non-specific) and Z-Ile-Glu(OMe)-Thr-Asp(OMe)-CH2F (z-IETD-fmk, specific
for caspase-8), were obtained from Calbiochem (Darmstadt, Germany).
Recombinant TNFα and recombinant human TRAIL/Apo2L were obtained
from Strathmann Biotech AG (Hamburg, Germany). Monochlorobimane was
obtained from Molecular Probes (Eugene, OR, USA). Rabbit polyclonal
antibodies (pAb) against human Akt, phospho-Akt (Ser471), p38-MAPK, and
phospho-p38-MAPK (Thr180/Tyr182), and mouse anti-caspase-8 monoclonal
antibody (mAb) (1C12), were obtained from Cell Signaling Technology
(Beverly, MA, USA). Mouse anti-pigeon cytochrome c mAb clone 7H8.2C12
and mouse anti-Bax mAb clone 6A7 were obtained from BD PharMingen (San
Diego, CA, USA). Mouse anti-human Bcl-2 (100) mAb, rabbit anti-human Bax
(N-20) pAb, goat anti-human Bid (C-20) pAb, rabbit anti-human NF-κB p65
(sc-109) pAb, and mouse anti-human tumour necrosis factor receptor 1 (TNF-
R1) (H-5) mAb, were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). Mouse anti-XIAP (MIHA/ILP-a) mAb was obtained from MBL
International Corporation (Woburn, MA, USA). Mouse anti-human CD95
(Apo1/Fas) (DX2) mAb was obtained from eBioscience (San Diego, CA, USA).
Rabbit anti-human FLIPL (the long isoform of the FLICE inhibitory protein)
pAb was obtained from Upstate Cell Signalling Solutions (Lake Placid, LY,
USA). Mouse anti-human TNF-RI/TNFRSF1A (16803) mAb, which specifi-
cally neutralizes TNF-R1, was obtained from R&D Systems (Minneapolis, MN,
USA). All peroxidase- and fluorescein isothiocyanate (FITC)-conjugated
immunoglobulin G antibodies were obtained from DAKO Diagnósticos, S.A.
(Barcelona, Spain). All other reagents were from Sigma (Madrid, Spain).
2.2. Cells and treatments
Human U937 (promonocytic), HL60 (myelomonocytic) and NB4 (acute
promyelocytic) leukemia cells, and stably Bcl-2-transfected U937 cells (U4
clone) [15], were grown as earlier indicated [16]. Stock solutions of
camptothecin and SB220025 (10 mM), LY294002, PD98059, SB203580 and
SP600125 (20 mM), U0126 (2.63 mM), Ac-DEVD-pNA and Ac-LEHD-pNA
(5 mM), z-VAD-fmk and z-IETD-fmk (25 mM), lonidamine (100 mM), and
monochlorobimane (200 mM), were prepared in dimethyl sulfoxide. Stock
solutions of cis-platinum(II)-diammine dichloride (cisplatin, 3.3 mM), TNFα
and TRAIL/Apo2L (100 μg/ml), were prepared in distilled water. All these
solutions were stored at −20 °C. Stock solutions of DAPI (100 μg/ml) and
propidium iodide (PI, 1 mg/ml) were prepared in phosphate-buffered saline
(PBS). A stock solution of As2O3 (100 mM) was prepared in distilled water.
These solutions were stored at 4 °C.
2.3. Determination of apoptosis, and measurement of caspase
activities
Distinctive characteristics of apoptotic cells were chromatin condensation/
fragmentation, as measured by DAPI staining and microscopy examination,
reduced (sub-G1) DNA content, as measured by PI staining and flow cytometry
examination, and phosphatidylserine translocation from the inner to the outer
layer of the plasma membrane, as indicated by cell surface binding of FITC-
labeled annexin V using flow cytometry assays. As a routine, we also examined
free trypan blue or PI penetration into the cells, as an indication of plasma
membrane integrity. Caspase-9 and caspase-3 activities were determined in in
vitro assays, using as substrates Ac-LEHD-pNA and Ac-DEVD-pNA,
respectively. Caspase-8 activation was evidenced by the appearance of pro-
caspase-derived cleavage fragments, as determined by immunoblot assays.
Annexin V binding was determined using a rh Annexin V/FITC Kit (Bender
MedSystems GmbH, Vienna, Austria), following the procedure described by the
manufacturer. A detailed description of all other procedures was presented in
preceding publications [16,17], and hence is omitted here.
2.4. Measurement of intracellular GSH content
The intracellular GSH content was determined by fluorometry after cell
loading with monochlorobimane, following the previously described procedure
[18].
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To obtain total cellular protein extracts, cells were collected by centrifuga-
tion, washed with PBS, and lysed by 5-min heating at 100 °C followed by
sonication in Laemmli's buffer containing a protease inhibitor cocktail, 10 mM
sodium fluoride, and 1 mM sodium orthovanadate. To obtain cytosolic extracts,
aimed at determining cytochrome c and Omi/HtrA2 release from mitochondria,
cells were collected for centrifugation, re-suspended in 100 μl of ice-cold PBS
containing 80 mM KCl, 250 mM sucrose, and 200 μg/ml digitonin, and kept onFig. 1. Apoptosis induction by As2O3 and TNFα in U937 cells. The figure shows the f
and D), annexin V binding to the cell surface (panel B), and reduction in DNA con
combination. (A) Cells were permeabilized and stained with DAPI, and the chrom
stained with annexin V, and the fluorescence determined by flow cytometry. Numbers
vertical dotted line. (C) Cells were permeabilized and stained with PI, and the fluor
Numbers in parentheses indicate the fraction of cells with sub-G1 DNA content. (D) C
for 24 h in the absence of the drug (TNF, As); or treated firstly for 24 h with TNFα alo
(As–TNF). Except when otherwise is indicated, As2O3 was used at 4 μM; TNFαwas u
were simultaneously applied. Z-VAD-fmk (50 μM, panel A) was applied 30 min befor
used. The bars in panels A and D represent the mean±S.D. of at least three determ
determinations with similar results.ice for 5 min. After centrifugation (10000×g for 15 min at 4 °C) the pellet was
discarded. To obtain mitochondrial extracts, aimed at determining Bax
translocation to mitochondria, cells were homogenized by repeatedly passing
them throughout a 25-gauge needle. The homogenate was first centrifuged at
1000×g for 10 min, and the supernatant centrifuged again at 10000×g for 20 min
to obtain the mitochondrial fraction, following the previously described
procedure [17]. Nuclear extracts, aimed at determining p65 NF-κB transloca-
tion, were obtained using the method of Schreibert et al. [19]. Fractions of total,
mitochondrial, cytosolic or nuclear extracts, containing equal protein amounts,requency of apoptotic cells, as determined by chromatin fragmentation (panels A
tent (panel C), in U937 cell cultures treated with As2O3 and TNFα, alone or in
atin examined by fluorescence microscopy. (B) Non-permeabilized cells were
in parentheses indicate the fraction of annexin V-positive cells, delimited by the
escence (as an indication of DNA content) was determined by flow cytometry.
ells were treated for 24 h with As2O3 or TNFα alone, and then allowed to recover
ne, washed, and then treated for 24 h with As2O3 alone (TNF–As); or vice versa
sed at 40 ng/ml; the treatments lasted 24 h; and the drugs in combined treatments
e treatment with As2O3 plus TNFα. As controls (Cont), drug-untreated cells were
inations, and the profiles in panels B and C are representative of one of two
1656 D. Amrán et al. / Biochimica et Biophysica Acta 1773 (2007) 1653–1663were analyzed by SDS-polyacrylamide gel electrophoresis, blotted onto
membranes, and immunodetected, as previously described [16].
2.6. Electrophoretic mobility gel shift assays
Nuclear extracts were obtained as indicated by Schreibert et al. [19]. A
double-strand oligonucleotide containing the consensus binding site for NF-κB
(5′-AGTTGAGGGGACTTTCCCAGGC-3′) was prepared. The conditions of
oligoprobe radioactive labeling, binding reaction, and electrophoretic separa-
tion, were exactly as described by López-Rodríguez et al. [20]. For competition
experiments, nuclear extracts were pre-incubated with 50-fold molar excess of
unlabelled oligonucleotide for 30 min at 4 °C before adding the labeled probe.3. Results
3.1. Death induction
We firstly examined the capacity of As2O3 and TNFα to
cause apoptosis in U937 promonocytic cells, as determined by
chromatin condensation. As indicated in Fig. 1A, As2O3 was
almost innocuous at 1–2 μM, and moderately toxic at 4 μM,
while TNFα was almost innocuous at all assayed concentra-
tions (from 20 to 80 ng/ml). When they were simultaneously
applied, TNFα and As2O3 synergistically induced apoptosis inFig. 2. Apoptosis induction in other myeloid cells lines, or using different cytokines
alone, and with the indicated concentrations of As2O3, alone (−) or in combination wi
agonistic anti-CD95 antibody (αFas) or TRAIL, alone or in combination with As2O3.
(CDDP), or 10 nM camptothecin (CPT), alone (−) or in combination with TNFα. The
when otherwise is indicated, As2O3 was used at 4 μM, TNFα at 40 ng/ml, and TRAILa concentration-dependent (from 1 to 4 μM As2O3) and time-
dependent (from 8 to 24 h) manner. Allowing for quantitative
differences inherent to the sensitivity of the used techniques,
this response was corroborated by measuring the fraction of
cells exhibiting surface binding of annexin V (Fig. 1B), as well
as the accumulation of cells with sub-G1 DNA content (Fig.
1C). Treatment with As2O3 for periods longer than 24 h also
slightly caused cell accumulation at the G2/M phase of the
growth cycle (result not shown). The pan-caspase inhibitor z-
VAD-fmk greatly decreased the As2O3 plus TNFα-provoked
cell death (Fig. 1A), indicating that it is bona fide caspase-
dependent apoptosis. Under the used conditions, the frequency
of cells permeable to PI or trypan blue, which may indicate
primary or secondary (apoptosis-derived) necrosis, was below
12% (results not shown).
The cooperation between antitumour drugs and cytokines is
generally explained by the capacity of the chemotherapeutic
drug to sensitize to cytokine-induced apoptosis. Nevertheless
the opposite effect, namely sensitization by TNFα to
chemotherapeutic drug-provoked apoptosis, was also reported
[21, and references therein]. For this reason, new determina-
tions were carried out in which As2O3 and TNFα were
sequentially applied. Pre-treatment with As2O3 followed byand antitumour drugs. (A) HL60 and NB4 cell cultures were treated with TNFα
th TNFα. (B) U937 cell cultures were treated with the indicated concentrations of
(C) U937 cell cultures were treated with 50 μM lonidamine (Lon), 4 μM cisplatin
frequency of apoptotic cells was determined by chromatin fragmentation. Except
at 100 ng/ml, and the treatments lasted 24 h. All other conditions were as in Fig. 1.
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while no potentiation was obtained using the opposite sequence
(Fig. 1D), indicating sensitization by As2O3 to TNFα-mediated
apoptosis.
For comparison, experiments were carried out using HL60
myelomonocytic and NB4 acute promyelocytic leukemia cells
instead of U937 cells, agonistic CD95 antibody and TRAIL
instead of TNFα, and the antitumour drugs lonidamine,
cisplatin and camptothecin, instead of As2O3. Determinations
of chromatin fragmentation indicated that: (i) As2O3 and TNFα
also cooperated to induce apoptosis in both HL60 and NB4 cells
(Fig. 2A). (ii) Treatment with CD95 antibody was innocuous,
and the apoptotic effect in combination with As2O3 was not
higher than that caused by As2O3 alone. On the other hand,
TRAIL caused per se a moderate, concentration-dependent
toxicity at 50 to 150 ng/ml. This cytokine cooperated with
As2O3 to induce apoptosis, but the effect was approximately
additive (Fig. 2B). Finally, no sensitization to TNFα-induced
apoptosis could be obtained using lonidamine, cisplatin or
camptothecin (Fig. 2C). These effects were qualitatively
corroborated by measuring cell surface annexin-V binding
and accumulation of cells with sub-G1 DNA content (results not
shown).Fig. 3. Activation of the extrinsic apoptotic pathway. In panels A, C, D and F, total ce
panels B and E apoptosis was determined at 24 h of treatment. (A) Cleavage-activatio
the appearance of 43 kDa and 18 kDa apoptosis-related fragments. (B) Frequency of
the absence or in the presence of the caspase-8-specific inhibitor z-IETD-fmk (50 μM
evidenced by the decrease in the 23-kDa Bid pro-form content. (D) TNF-R1 expressio
cells in cultures treated with As2O3, alone or with TNFα, either in the absence or the
expression levels, in cells subjected to the indicated treatments. Z-IETD-fmk and n-
represent the mean±S.D. of at least three determinations (*Pb0.01, Student's t test
determinations with similar results. In these experiments, the levels of α-tubulin (C,
conditions were as in Figs. 1 and 2.3.2. Activation of the receptor-mediated pathway
Then, we wanted to determine caspase-8 activation, which
represents a critical event in the execution of the extrinsic
apoptotic pathway. As indicated in Fig. 3A, treatment with
As2O3 plus TNFα caused pro-caspase-8 cleavage/activation,
while As2O3 alone and TNFα alone were almost ineffective.
Control determinations indicated caspase-8 activation by
treatment with TRAIL alone, which as indicated above sufficed
to cause apoptosis. By contrast no activation was observed upon
treatment with As2O3 plus CD95 antibody or cisplatin plus
TNFα, which failed to cause or to potentiate apoptosis,
respectively (see Fig. 2A and C). The caspase-8 inhibitor z-
IETD-fmk reduced the toxic action of As2O3 plus TNFα to
a level similar to that produced by As2O3 alone (Fig. 3B),
corroborating the importance of this caspase for apoptosis.
Finally, As2O3 plus TNFα also caused cleavage/activation of
Bid, a substrate of caspase-8, as revealed by the decrease in
the amount of the 23-kDa Bid pro-form (Fig. 3C).
Treatment with As2O3 alone and with As2O3 plus TNFα
activated TNF-R1 expression, as determined by immunoblot
assays, while no activation was obtained with TNFα alone or with
cisplatin plus TNFα (included as a control) (Fig. 3D). Flowllular protein extracts were assayed by immunoblot at 16 h of treatment, while in
n of pro-caspase-8 in cells subjected to the indicated treatments, as evidenced by
apoptotic cells in cultures treated with As2O3, alone or and with TNFα, either in
). (C) Cleavage/activation of Bid in cells subjected to the indicated treatments, as
n levels, in cells subjected to the indicated treatments. (E) Frequency of apoptotic
presence of 20 μg/ml neutralizing TNF-R1 antibody (n-αTNFR1). (F) C-FLIPL
αTNFR1 were applied 30 min before treatments. The results in panels B and E
). The results in panels A, C, D and F are representative of one of at least two
F) and total p38-MAPK (D) were also measured as loading controls. All other
Fig. 4. Activation of the intrinsic (mitochondrial) apoptotic pathway. (A, B) The
presence of cytochrome c (Cyt c) and Omi/HtrA2 (Omi) in the cytosol (cyto),
and of Bax in cytosolic and mitochondrial fractions (mito) (A), and the total
cellular levels of XIAP, Bcl-2 and Bax (B), were determined by immunoblot
using cytosolic, mitochondrial, and total cellular protein extracts, respectively.
The level of α-tubulin was also measured as a loading control. (C) Caspase-9
and caspase-3 activities were determined in in vitro assays using as substrates
Ac-LEHD-pNA and Ac-DEVD-pNA, respectively. The results (mean±S.D. of
three determinations) are indicated in relation to untreated cells (Cont), which
received the arbitrary value of one. The values in panels A and B are
representative of one of two determinations. Except when otherwise indicated,
the measurements were carried out at 16 h of treatment. All other conditions
were as in Fig. 1.
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detect cell surface receptor expression (results not shown).
Incubation with anti-TNF-R1 neutralizing antibody decreased
the As2O3 plus TNFα-provoked cell death (Fig. 3E), which
corroborates the importance of this receptor in mediating apop-
tosis potentiation. Finally, treatment with As2O3 plus TNFα
decreased the expression of the long isoform of the caspase-8
antagonist c-FLIP (c-FLIPL) (Fig. 3F). Control determinations
indicated c-FLIPL decrease upon treatment with TRAIL alone,
which as indicated above caused caspase-8 activation, but not by
treatments with As2O3 plus anti-CD95 antibody or cisplatin plus
TNFα, which failed to activate caspase-8. The short isoform of
c-FLIP (c-FLIPS) could not be detected in U937 cells [22].
While treatment with As2O3 alone activated TNF-R1 expres-
sion, As2O3 toxicity was not decreased by incubation with anti-
TNF-R1 neutralizing antibody (Fig. 3E) or with caspase-8
inhibitor (Fig. 3B). Moreover, incubation with an anti-TNFα-
blocking antibody was equally ineffective, and ELISA assays
failed to detect TNFα increase in the supernatant of As2O3-treated
cells (results not shown). This excludes a possible intervention of
TNFα/TNF-R1 in mediating the apoptotic action of As2O3.
3.3. Activation of the mitochondrial pathway
As indicated above, As2O3 may induce apoptosis through
direct binding to mitochondria. In addition, the cleavage/
activation of Bid (see Fig. 3C) suggests the engagement of the
mitochondrial pathway in As2O3 plus TNFα-provoked apopto-
sis. For these reasons, we examined the behaviour of factors
critical for the stimulation of this pathway, such as the release of
the mitochondria-localized proteins cytochrome c and Omi/
HtrA2, the expression and/or localization of XIAP, Bcl-2, and
Bax, and the activation of caspases -9 and -3. The obtained
results are summarized in Fig. 4. While changes in cytochrome
c, Omi/HtrA2 and XIAP were very low in cells treated with
As2O3 alone, As2O3 plus TNFα clearly elicited cytochrome c
and Omi/HtrA2 release from mitochondria, as revealed by
immunoblot assays using cytosolic extracts (Fig. 4A). This
treatment also caused a decrease in the total XIAP levels (Fig.
4B). Total Bcl-2 and Bax expression remained almost unaffected
(Fig. 4B). However As2O3 induced Bax translocation to
mitochondria, and this effect was potentiated by co-treatment
with TNFα, as demonstrated by immunoblot using mitochon-
drial and cytosolic extracts (Fig. 4A). This observation was
qualitatively corroborated by flow cytometry assays using an
anti-Bax antibody (6A7 clone), which specifically recognizes a
conformationally active Bax isoform [16] (result not shown).
Finally, As2O3 induced LEHDase (indicative of caspase-9) and
DEVDase (indicative of caspase-3) activities, and these effects
were increased by co-treatment with TNFα (Fig. 4C). These
results indicate that co-treatment with As2O3 plus TNFα in fact
potentiates the activation of the intrinsic executioner pathway.
3.4. Effects of Bcl-2 over-expression
To investigate the relationship between the extrinsic and
intrinsic pathways, experiments were carried out using Bcl-2-transfected U937 cells (U4 clone), since Bcl-2 is known to block
the apoptotic machinery at the mitochondrial level. Preliminary
determinations indicated an approximately eight-fold increase in
Bcl-2 content in the U4 cells, in relation to the non-transfected
cells (results not shown). It was found that U4 cells not only were
unable to undergo cytochrome c release (Fig. 5A), but also failed
to undergo apoptosis induction (Fig. 5B), caspase-8 activation
(Fig. 5C), and c-FLIPL down-regulation (Fig. 5D), in response to
As2O3 plus TNFα. However, TNF-R1 expression was still
increased in the U4 cells (Fig. 5D). This indicates that the
execution of the extrinsic pathway is under mitochondrial
control, which acts at some step(s) between receptor expression
and caspase-8 activation.
3.5. Akt phosphorylation, intracellular GSH, and NF-κB
activation
Earlier studies indicated that As2O3 may affect the phosphor-
ylation/activation of Akt [12,23,24], an that this kinase protects
Fig. 5. Effects of Bcl-2 over-expression. The experiments were carried out using Bcl-2-transfected U937 cells (U4 clone). Non-transfected cells (U937) were
occasionally included for comparison. (A) Release of cytochrome c to the cytosol, (C) cleavage/activation of caspase-8, and (D) expression levels of TNF-R1 and c-
FLIPL, at the indicated times of treatment with As2O3 plus TNFα. (B) Frequency of apoptotic cells, at 24 h of treatment. The results in panels A, C and D are
representative of one of at least two determinations. The results in panel B represent the mean±S.D. of three determinations. All other experimental conditions were as
in Figs. 1, 3 and 4.
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alteration in Akt phosphorylation was interpreted as a response
to the generation of reactive oxygen species elicited by As2O3
[23,24]. In addition, we recently reported that PI3K/Akt
inhibitors decrease the intracellular level of reduced glutathione
(GSH), which is a strict determinant of As2O3 toxicity [26, and
references therein]. For these reasons, experiments were carried
out to analyze Akt phosphorylation and intracellular GSH in
U937 cells treated with As2O3, alone and in combination with
TNFα. As indicated in Fig. 6A, B, the treatments did not cause
significant alterations in Akt phosphorylation, nor altered the
GSH content. This contrasts with the decrease in both
parameters provoked by the PI3K inhibitor LY294005, which
was included as a control. Moreover, in our experiments As2O3
did not cause detectable alterations in intracellular reactive
oxygen species content, as determined using the peroxide-
sensitive probe dichlorodihydrofluorescein diacetate (results not
shown).
It is known that TNFα activates NF-κB, a transcription factor
with anti-apoptotic action [27]. In addition, it was reported that
As2O3 may down-regulate NF-κB activation in myeloid cells
[28]. For these reasons, we wanted to measure NF-κB activationin cells treatedwithTNFα, alone and in combinationwithAs2O3.
It was observed that treatment with TNFα alone stimulated
NF-κB binding to its DNA consensus sequence, but the binding
was not reduced by co-treatment with As2O3 (Fig. 6C). In
agreement with this, As2O3 failed to prevent the TNFα-provoked
stimulation of p65-NF-κB translocation to the nucleus (Fig. 6D).
Collectively, these results indicate that the sensitization byAs2O3
to TNFα-provoked apoptosis may not be explained by altera-
tions in Akt phosphorylation, GSH level, or NF-κB activity.
3.6. MAP kinase signalling
MAP kinases are essential factors in apoptosis signalling, and
TNFαwas reported to stimulate JNK and p38-MAPK activation
[27]. To investigate the possible involvement of MAPKs on
apoptosis induction by As2O3 plus TNFα, experiments were
carried out using the p38 inhibitors SB203580 (10 μM) and
SB220025 (1 μM), the JNK inhibitor SP600125 (10 μM), and
the MEK/ERK inhibitors PD98059 (20 μM) and U0126
(2.5 μM). These concentrations were selected from preceding
studies, which indicated that they effectively prevented kinase
activation without causing per se significant cell death [16,29].
Fig. 6. Akt phosphorylation, GSH content, and NF-κB activation. (A) Relative
levels of total and phosphorylated Akt (T-Akt and P-Akt, respectively), as
revealed by immunoblot assays, at the indicated times of treatment with As2O3,
alone or with TNFα, and at 24 h of treatment with 30 μM LY294002 (LY, used
as a control). (B) Intracellular GSH content at 24 h of treatment with As2O3,
alone or with TNFα, or with LY294002 (used as a control). The values are
represented in relation to untreated cell cultures (approximate GSH content,
9.0 nmol/106 cells), which received the arbitrary value of one. (C) NF-κB
binding activity, as determined by gel shift assays at the indicated times of
treatment with TNFα, alone or with As2O3. The positions of bound (NF-κB) and
free (arrow) oligoprobe are indicated. (D) Nuclear translocation of p65 NF-κB,
as determined at 16 h of treatment by immunoblot using nuclear protein extracts.
The corresponding cytosolic fractions were used as a control. The experiments
were repeated twice in panels A and D, and three times in panels B and C. All
other conditions were as in Fig. 1.
1660 D. Amrán et al. / Biochimica et Biophysica Acta 1773 (2007) 1653–1663As indicated in Fig. 7A, the p38-MAPK inhibitors did not affect
apoptosis induction by As2O3 alone, but they attenuated
apoptosis potentiation by As2O3 plus TNFα. By contrast, noattenuation was observed using the JNK and MEK/ERK
inhibitors. P38-MAPK inhibitor also attenuated cytochrome c
and Omi/HtrA2 release, caspase-8 and Bid cleavage/activation,
and Bax translocation (Fig. 7B). Immunoblot assays indicated
that treatments with As2O3 caused p38-MAPK activation, as
revealed by the increase in protein phosphorylation, and the
activation was higher in combination with TNFα (Fig. 7C). Of
note, treatment with TNFα alone, which as indicated above
failed to cause apoptosis, sufficed to activate p38-MAPK (Fig.
7C), and this effect was blocked by anti-TNF-R1 neutralizing
antibody (Fig. 7D). Thus, p38-MAPK activation is a necessary,
but not sufficient event for TNF-R1-mediated apoptosis.
4. Discussion
The results in this work indicate that the anti-leukemic drug
As2O3 cooperates with TNFα in inducing apoptosis in U937
promonocytes and other human myeloid leukemia cell lines.
This response is attributable to the capacity of As2O3 to
sensitize the cells to the action of TNFα, to which they are
normally refractory. As2O3 and TRAIL also cooperate in
inducing apoptosis. Nevertheless U937 cells are moderately
sensitive to TRAIL, as measured by caspase-8 activation and
apoptosis induction, and the potentiation by As2O3 of TRAIL
toxicity is relatively lower (additive effect) than in the case of
TNFα. Sensitization by As2O3 appears as a drug-specific
response, since lonidamine, cisplatin and camptothecin failed to
cooperate with TNFα in inducing apoptosis and, at least in the
case of cisplatin, in activating the receptor-mediated pathway.
This may be surprising, since campthocecin and other chemo-
therapeutic drugs stimulated TNFα-provoked apoptosis in other
cell types [10,30]. The reason for such discrepancy remains to
be determined.
The present results also indicate that sensitization by As2O3 to
TNFα-induced apoptosis involve the activation of the receptor-
mediated pathway and the potentiation of the mitochondrial
pathway, and that both pathways contribute to the final apoptotic
response. Although As2O3 is a mitochondria-targeting agent,
there are reports proving that this drug may activate the
mitochondrial or the receptor-mediated pathway, depending on
the used cell model. An example of this was given by the
functional status of p53 in multiple myeloma cells. Thus, in
myeloma cells bearing wild type p53 As2O3 increased TRAIL
receptor expression, but failed to activate caspase-8, and
apoptosis was primarily executed throughout the mitochondrial
pathway. By contrast, in p53-null myeloma cells, cells with
mutated p53, or cells with siRNA-silenced p53, which are more
sensitive to As2O3, the drug increased TRAIL and TRAIL
receptor expression, caused c-FLIPL down-regulation, and
elicited caspase-8 and Bid activation, with later engagement of
the mitochondrial pathway [11,31,32]. Of note, U937 promono-
cytic cells are p53-null cells [33], and in our experiments
treatment with As2O3 alone sufficed to increase TNF-R1
expression, but in spite of it the drug failed to activate caspase-
8/Bid. However the combination of As2O3 plus TNFα, which
increased TNF-R1 expression and also caused c-FLIPL down-
regulation, elicited caspase-8/Bid activation. The potentiation of
Fig. 7. p38-MAPK activation and effect of MAPK inhibitors. (A) Frequency of apoptotic cells in cell cultures treated for 24 h with As2O3, alone or with As2O3, either
in the absence (−) or the presence of the p38-MAPK inhibitors SB203580 (SB1, 10 μM) and SB220025 (SB2, 1 μM), the JNK inhibitor SP600125 (SP, 10 μM), and
the MEK/ERK inhibitors PD98059 (PD, 20 μM) and U0126 (U, 2.5 μM). The results indicate the mean±S.D. of at least three determinations (*Pb0.005, Student's
t test). (B) Release of cytochrome c and Omi/HtrA2, activation of caspase-8 and Bid, and translocation of Bax to mitochondria, in cells treated for 16 h with As2O3
plus TNFα, alone or with SB203580, as determined by immunoblot using cytosolic (cytochrome c, Omi/HtrA2), cytosolic and mitochondrial (Bax), and total
cellular (caspase-8, Bid) protein extracts. (C) Relative levels of total and phosphorylated p38-MAPK (p38-T and p38-P, respectively) upon treatment for the
indicated time periods with As2O3 alone, TNFα alone, or As2O3 plus TNFα, as determined by immunoblot. (D) Relative levels of phosphorylated p38-MAPK, upon
treatment for 16 h with TNFα, alone or in the presence of neutralizing TNF-R1 antibody (n-αTNFR1). The results in panels B–D are representative of one of at least
two determinations. The kinase inhibitors and n-αTNFR1 were applied 30 min before the treatments. All other conditions are as in Figs. 1, 3 and 4.
1661D. Amrán et al. / Biochimica et Biophysica Acta 1773 (2007) 1653–1663the mitochondrial pathway by As2O3 plus TNFα involves the
concurrence of Bid and Bax activation, which favours protein
release from mitochondria, and XIAP down-regulation, which
relieves caspases from the inhibitory action of that protein [6]. As
indicated above, Bid activation serves to engage the mitochon-
dria in cytokine-initiated apoptosis. Bax is a substrate of p38-
MAPK, and this kinase was demonstrated to regulate Bax
phosphorylation/activation and translocation to mitochondria
[34]. Hence, Bax activation may represent a key factor to explain
the regulation by p38-MAPK of As2O3 plus TNFα-provoked
apoptosis. Finally, recent reports characterized XIAP expression
as a factor which determines cell resistance against cytokine-
mediated apoptosis, and XIAP down-regulation as a central event
explaining the synergism between TNFα family cytokines and
chemotherapeutic drugs [35,36].
Akt and NF-κB regulates the expression and activity of
several pro-apoptotic or anti-apoptotic proteins, including c-FLIP
and IAPs [12,28,37]. Moreover, Akt may regulate the synthesis
and activity of γ-glutamylcysteine synthetase, the key-limiting
enzyme of GSH biosynthesis [16,38]. The effect of As2O3 on Akt
is controversial, since there are reports indicating that the drug
decreases [12,23] or increases [24] Akt phosphorylation in
leukemia cells. However in our experiments As2O3 did not cause
significant alterations in Akt phosphorylation or intracellular
GSH content in U937 cells treated with As2O3, alone and with
TNFα. In the same manner, the behaviour of NF-κB does not
satisfactorily explain the sensitizing action of As2O3, since thedrug failed to prevent the TNFα-provoked NF-κB activation in
U937 promonocytic cells. As an alternative explanation, c-FLIP
and XIAP down-regulation might be the consequence of
increased ubiquitinization/proteasome-mediated protein degrada-
tion, as indicated by some authors [39,40]. Actually, earlier
studies reported an increase in ubiquitin-conjugated proteins in
arsenic-treated cells [41]. Moreover, Omi/HtrA2 is released from
mitochondria upon treatment with As2O3 plus TNFα, and this
protein has been characterized as a serine protease which targets
and degrades IAPs [42,43].
Enforced expression of Bcl-2 and Bcl-XL is frequently used as
a tool to block the mitochondrial apoptotic cascade, and to check
the contribution of mitochondria to the final apoptotic effect. In
this regard, earlier reports indicated that Bcl-2 over-expression did
not prevent or had minimal effects on apoptosis generation by
TRAIL in HL60 cells [37], by As2O3 in multiple myeloma cells
with mutated p53 [31], by mytramycin A plus TNFα in TF-1
human erythroleukemia cells [10], and by flavopiridol plus
TRAIL in U937 cells [35]. Thus, in those experimental models the
mitochondrial pathway was dispensable for apoptosis execution.
By contrast, in our experiments mitochondrial activation played
an important role, since Bcl-2 over-expressing cells were
prevented from undergoing caspase-8 activation and apoptosis
in response to As2O3 plus TNFα. The blockade of caspase-8
could be explained by the inability of the Bcl-2-over-expressing
cells to down-regulate c-FLIP levels, but additional regulation at
other steps of the DISC machinery may not be excluded.
1662 D. Amrán et al. / Biochimica et Biophysica Acta 1773 (2007) 1653–1663In summary, co-treatment with low As2O3 concentrations
sensitizes myeloid leukemia cells to apoptosis induction by
TNFα, following a process which involves the interplay of the
extrinsic (receptor-mediated) and mitochondrial pathways. On
the one hand, the increase in TNF-R1 expression and down-
regulation of c-FLIP expression lead to caspase-8 activation,
and caspase-8-mediated Bid cleavage together with Bax
activation and XIAP down-regulation facilitate mitochondrial-
dependent caspase-9 and -3 activation. In turn, mitochondrial
pathway activation regulates caspase-8 activation and execution
of the extrinsic pathway. By potentiating the apoptotic response,
combined treatments may offer new opportunities for the use of
As2O3 and TNFα as therapeutic agents.
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